) recently announced the availability of NovoSeven with a
pre-filled syringe for the treatment of bleeding episodes in
hemophilia patients. This will make treatment easier given the
system's ease of use, flexibility and a quick reconstitution
BAYER A G -ADR (BAYRY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
In Oct 2012, the treatment was approved by both the European
Medicines Agency (EMA) and the US Food and Drug Administration
(FDA). The product will be called "NovoSeven with pre-filled
syringe" and "NovoSeven RT with MixPro" in the EU and the US,
Meanwhile Novo Nordisk is looking towards its two newly approved
diabetes drugs, Tresiba and Ryzodeg, for driving long-term
In Jan 2013, Novo Nordisk received approval in the EU (covering
all 27 states) for both Tresiba and Ryzodeg. In the EU, Novo
Nordisk is planning to launch Tresiba first and Ryzodeg a year
later. Tresiba and Ryzodeg will be available in Novo Nordisk's
latest prefilled insulin pen named FlexTouch in Europe.
The Japanese Ministry of Health, Labour and Welfare (MHLW)
approved Tresiba and Ryzodeg for the treatment of diabetes in
September and December 2012, respectively. A few days back, Novo
Nordisk received approval of the price of Tresiba from MHLW.
However, in Feb 2013, Novo Nordisk faced a setback when the FDA
declined to approve both diabetes candidates on the basis of the
submitted data. The FDA issued a complete response letter (CRL)
asking Novo Nordisk to conduct a dedicated cardiovascular
outcomes study and provide additional cardiovascular data.
Moreover, the FDA said that it will not grant approval to these
candidates until the company resolves the issues mentioned in a
warning letter given by the FDA in Dec 2012. The warning letter
specified violations of current good manufacturing practice
(CGMP) regulations for finished pharmaceuticals at the company's
Novo Alle, Bagsvaerd Denmark facility.
Though the launch of Novoseven with a prefilled syringe is
encouraging, we are concerned about the presence of big players
) for the control and prevention of bleeding episodes in
Novo Nordisk currently carries a Zacks Rank #2 (Buy). Other
large-cap pharma companies like
Eli Lilly and Company
) also carry a Zacks Rank #2.